Bayer's Q2 Beat Hides a €2.7 Billion Cash Sucker Punch

A clean headline beat, a weaker cash story

Bayer passed the simplest test investors look for in a quarter: the headline numbers beat. Q2 adjusted EPS of 0.2735 beat the 0.2203 consensus, revenue of €12.52 billion topped the €12.31 billion forecast, and management said it remained on track with full-year guidance. That is the kind of quarter that suggests the core business is still functioning and the strategy has not fallen apart.

The harder test is the cash flow statement. Bayer reported negative free cash flow of EUR 2.7 billion in H1, and management tied much of that to EUR 2.5 billion in litigation-related payouts. In other words, the operating result held up better than the bank account.

That tension is why investor reactions can split. Bulls can point to a classic beat-and-hold-guidance quarter and argue the base business is finally earning more trust. Bears can counter that litigation-driven cash drains are hard to discount because they may keep recurring. The clearest read is straightforward: Bayer looks operationally intact, but the cash bill is still the main concern.

Division performance supports stability, not yet a strong recovery narrative

At the group level, Bayer posted 3% currency- and portfolio-adjusted group sales growth in the first half and stayed on track for the year. That matters because it shows the divisions are not slipping while financing activity masks the problem. Still, this looks more like resilience than a clean turnaround.

Crop Science is the strongest operating pillar

Crop Science remains the clearest bright spot. The division delivered sales up 5.5% in the first half, while its EBITDA margin expanded to 31%. That combination suggests better commercial execution and a more profitable sales mix, not just a good commodity backdrop. If one division can carry the "stable operator" label today, it is Crop Science.

Pharmaceuticals: real progress, but Eylea still dominates the narrative

Pharmaceuticals is improving in places, but it is not yet a fully reassuring comeback story. Strong growth in NUBEQA and KERENDIA shows Bayer still has active growth drivers, but Eylea sales fell 27% on biosimilar pressure. That decline matters because it affects how the market views the segment's near-term ceiling. For now, Pharmaceuticals looks more like a work in progress than a clean recovery.

Consumer Health is holding up, but margins are not the strong point

Management said Consumer Health registers slightly higher sales and lower earnings. That points to a business that still has brand strength and shelf presence, but not one that is suddenly gaining much better profitability. The division adds breadth to the group, but it is not strong enough on its own to offset the heavier issues elsewhere.

The market still cares more about litigation cash flow than incremental growth

There is at least one reassuring datapoint outside the quarter itself: Bayer said it ended 2025 within the improved corridor, which supports management's view that the broader plan remains intact. Even so, operating growth alone is not enough to push the stock into a more confident valuation. As long as performance remains solid in ag, uneven in pharma, and modest in consumer health, investors will keep weighing litigation cash flow heavily.

De-risking the balance sheet is now the real catalyst

Another small EPS beat is no longer the main event. What matters now is whether Bayer can make the capital structure look more manageable after bringing in EUR 3.0 billion in Apollo equity and lowering net financial debt guidance to EUR 29 billion to EUR 30 billion even after that financing support and a $5 billion bond sale. The financing has bought time, but it has not solved the broader cleanup story.

Management also said free cash flow to be heavily impacted by settlement payments in 2026, so the near-term debate is simple: this is still a balance-sheet repair story first and an operating story second.

What could move the stock higher

• Crop Science stays strong. If the division that is doing the most to prove operational discipline keeps performing, Bayer gets more credit for a real business base.
• Pharmaceuticals stabilizes. Bayer does not need a home run here, but less Eylea drag and fewer biosimilar surprises would improve the sentiment quickly.
• Net debt keeps improving. After the Apollo deal and bond issuance, continued progress toward the new debt target would matter more than another modest earnings beat.

What would break the story

• Debt repair stalls. If net debt stops moving the right way after all the financing activity, the cleanup narrative weakens fast.
• Litigation cash outflows worsen. Settlement payments are already the main cash drain; a bigger hit would put fresh pressure on the story.
• Eylea erosion accelerates. Faster biosimilar loss in ophthalmology would undermine the idea that Pharmaceuticals is stabilizing.

Another beat can keep Bayer on investors' radars. Visible balance-sheet repair is what would make it more buyable.